A 60 year old woman non-smoker with bronchial asthma of 6 years' duration, treated with aminophylline, salbutamol, and oral corticosteroids, was admitted because of increasing dyspnoea and productive cough. On examination she was in moderate respiratory distress with inspiratory and expiratory wheezes. Her chest radiograph was interpreted as normal. Two consecutive sputum examinations requested by a junior doctor reveal "malignant" cells.
There is a general agreement that a finding of malignant cells in the sputum of a person with a normal chest radiograph warrants fibreoptic bronchoscopy to locate the malignant tumour with a view to subsequent surgical removal.' 2 This recommendation is based on the inverse correlation between survival after surgical treatment of lung cancer and stage of the tumour. It has been reported that 24-42% of patients with stage I disease were alive at six years, whereas only 10% of those with stage II or III survived for five years. 3 The best survival figures after surgical resection have been reported in symptom free patients with radiologically occult disease detected by positive sputum cytology. 48 Even if we allow for the effect of "lead time" (whereby a longer survival noted in those diagnosed earlier is explained by a longer period of observation of the disease rather than by alteration in its course) most clinicians would still favour diagnosis of bronchial carcinoma at the earliest stage possible.
It has been claimed that "exfoliative cytology is a definitive diagnostic test for lung cancer,"9 and that its accuracy has advanced to the point "that the term 'exfoliative' cytology should be replaced by 'diagnostic' cytology"."0 Malignant cells have, however, been found in the sputum in up to 10-3%9 of cases in the absence of lung cancer, mainly among-patients with pulmonary infections9 l and bronchial asthma. l 2 How certain is the diagnosis of lung cancer in a symptomless person with a normal chest radiograph and malignant cells in the sputum? Or, in other words, what is the positive predictive value of sputum cyto-logy for lung cancer in the absence of other indicators of malignancy?
The predictive value of a test depends on its reliability, sensitivity, and specificity, and on the prevalence of the disease in the population from which the patient is drawn ("pretest probability" or "prior probability of disease"). ' 3 The reliability of a test is defined as its precision. A reliable test is one which, when applied repeatedly to the same specimen or patient, will produce the same or a similar result. Test reliability is commonly expressed in terms of its reproducibility. Test sensitivity is defined as the proportion of persons with a given disease who give a positive response to the test. The specificity of a test is defined as the proportion of persons without the disease who give a negative response to the test. There is a tendency to confuse test sensitivity with positive predictive value, which is defined as the proportion of persons giving a positive response to the test who have the disease. The term "false positive" rate is often incorrectly defined as the ratio between false positive and true positive test results. The correct definition of a false positive rate is the proportion of persons without the disease who give a positive response to the test. Thus false positive rate = Ispecificity.
The following is a review of published data on the reliability, sensitivity, and specificity of sputum cytology for lung cancer, in an attempt to estimate the positive predictive value of a finding of malignant cells in the sputum in a symptomless person with a normal chest radiograph. The pretest probability of preclinical lung cancer is derived from lung cancer incidence rates and from estimates of the duration of the presymptomatic phase of lung cancer.
Reliability of pulmonary cytology REVERSIBILITY OF ABNORMALITIES IN SPUTUM CYTOLOGY
The cytological abnormalities of sputum are usually classified as mild, moderate, and marked atypia, and positive identification of carcinoma cells.5 -Studies have indicated a sequential progression from mild to moderate and severe atypia, carcinoma in situ, and invasive cancer.'4-"6 It is believed that the earlier stages of this sequence are reversible. Evidence that 14 18 -21 revealed that the ratio between the numbers of specimens classified as showing marked atypia and those believed to contain carcinoma cells varied from 0-2:1 to 9:1; the ratio between moderate.atypia and carcinoma cells varied from 2:1 to 32:1. Even within the National Cancer Institute Cooperative Early Lung Cancer Detection Program,5 there were considerable differences in the relative numbers of specimens interpreted as containing cells with moderate atypia, marked atypia, and carcinoma cells (table 1) .
We know of only one study of interobserver reproducibility in the interpretation of sputum cytological findings. Evans and Shelley24 asked a panel of independent experts to reexamine 120 sputum cytology slides provided by six hospital centres, and classify them into the following categories of cell atypia: 1-normal; 2 hyperplasia, squamous metaplasia, or changes of the order seen in inflammation; 3-dyskaryosis or atypical metaplasia; 4-suggestive of malignancy; and 5-diagnostic of malignancy. Each hospital centre that provided the slides was asked that those originally classified in categories 4 and 5 should have histological or clinical confirmation or both. The "gold standard" for the remaining categories of cell atypia was a consensus diagnosis, reached by discussion among the experts after each of them had submitted his own diagnosis. "False positives" were defined as expert diagnoses of grade 4 or 5 in a slide whose consensus diagnosis was normal or grade 2. "False negatives" were expert diagnoses of "normal" or grade 2 in a slide originally diagnosed by the providing centre as grade 4 The third piece of information necessary for the determination of the predictive value of a test is the prevalence of the disease in the population from which the patient is drawn ("pretest probability" or "prior probability of disease"). ' (table 4) . Squamous cell cancer often originates centrally and grows as a thin sheet replacing the mucosa, thus escaping radiographic detection but readily shedding malignant cells into the sputum.5 For squamous cell cancer, the duration of the total preclinical phase-that is, from the first cell division to the earliest possible radiograph diagnosis (1 cm tumour diameter) is 7-2 years (30 doublings); to the time of usual diagnosis (3 cm tumour diameter) it is 8-4 years (35 doublings); and to death (10cm in tumour diameter) it is 9-6 years (40 doublings). We do not know the minimum tumour size needed to shed malignant cells into the sputum. Assuming that exfoliation of malignant cells begins when the tumour has a 1 mm diameter, it would take 10 doublings or 2-4 additional years to reach the minimum detectable size by chest radiograph (1 cm). On the assumption that exfoliation begins when the tumour consists of 1000 cells only, it would take 20 doublings, or 4-8 years, for the tumour to reach the minimum detectable size radiographically.
There have been sporadic studies of persons in whom the transition from marked atypia to histologically confirmed lung cancer occurred after a delay of from 6 months to 14 years. 16 22 These reports indicate that the duration of the detectable preclinical phase of lung cancer is highly variable, probably because of differences in tumour growth rates. We know of only one systematic cytological follow up of a high risk population from which the duration of the detectable preclinical phase of lung cancer can be estimated. In their initial"4 and updated'5 report, Saccomanno et al described the follow up of 38 uranium miners who developed invasive squamous cell lung cancer after an average duration of mild atypia of 2-8 years, of moderate atypia of 4-2 years, of marked atypia of 1-2 years, and of carcinoma in situ of 3 26 years. If we define the detectable presymptomatic phase of lung cancer as the period during which cells with marked atypia or carcinoma cells are shed by a symptomless person with a normal chest radiograph, then the lead time from detection of cells with marked atypia to invasive cancer calculated from these data is 4-48 years, while the average interval from first detection of carcinoma cells to tumour detection is 3-26 years. These values are consistent with those deduced from the theoretical model above.
Positive predictive value of sputum cytology Additional studies are needed to define better the reliability of sputum cytology and the false positive rate relative to an undisputed gold standard. We consider, however, that our survey of published data justifies the following assumptions as a basis for an estimate of the probability of lung cancer in a 60 year old nonsmoking woman with bronchial asthma and a normal chest radiograph. The assumptions were deliberately biased towards an overestimate of the probability of lung cancer.
(1) The risk of cancer in a smoker is 10 times that of a non-smoker.4344 (2) The risk of lung cancer in a patient with bronchial asthma is the same as that in patients of the same sex, age, and smoking habit without bronchial asthma. Exfoliative sputum cytology is not a definitive diagnostic test for lung cancer. As in the case of all diagnostic aids, its positive predictive value depends not only on its sensitivity and specificity but also on the pretest probability of the disease. As in all other tests, when the pretest likelihood of disease is low, a positive result is not particularly helpful in confirming the disease, since the false positive results outnumber true positives. On the other hand, in a high risk population a finding of even moderate atypia might have a strong positive predictive value for lung cancer. The decision on whether or not to do a cytological examination of the sputum should be based on the prior estimate of the likelihood of lung cancer given the patient's risk indicators, symptoms, and signs.
Should this middle aged, non-smoking woman with bronchial asthma have had her sputum examined cytologically to detect early pulmonary cancer? The results of recent studies do not provide definitive and conclusive evidence that early diagnosis of lung cancer reduces the mortality from this disease.5 -53 The inverse correlation between survival after surgical resection of lung cancer and stage of the tumour may be due merely to lead time or sampling biases.8 Screening for lung cancer therefore is not specifically recommended unless performed in the context of an experimental trial. 54 What is the threshold of the pretest probability of presymptomatic lung cancer that would justify screening by sputum cytology in such trials? We have no ready answer to this question. The decision should be based on the trade off between the possible (but so far unproved) benefit from early surgical resection of lung cancer and the cost of screening plus harm inflicted on patients with false positive results in terms of anxiety, morbidity, and mortality from subsequent examinations and surgery. As with every other test, cytological examination of the sputum should be undertaken-both in the setting of a screening trial and in diagnostic investigation of individuals-only if its estimated positive predictive value is considered sufficiently high for a positive result to bring about a change in the patient's
